1. Assessing bleeding risk in 18 children with Osteogenesis imperfecta.
- Author
-
Léguillier, Teddy, Favier, Rémi, Harroche, Annie, Lasne, Dominique, Bachelot‐Loza, Christilla, Borgel, Delphine, Boussaroque, Agathe, Pascreau, Tiffany, Lallemant‐Dudek, Pauline, Gkalea, Vasiliki, Haguet, Marie‐Clotilde, Cormier‐Daire, Valérie, Beaudeux, Jean‐Louis, Monnot, Sophie, Lapillonne, Hélène, Baujat, Geneviève, Forin, Véronique, and Nivet‐Antoine, Valérie
- Subjects
OSTEOGENESIS imperfecta ,HEMORRHAGE ,PLATELET function tests ,ENDOTHELIUM - Abstract
Keywords: Osteogenesis imperfecta; bleeding disorders; vascular disease; platelet function tests; endothelial activation markers; hemorrhage EN Osteogenesis imperfecta bleeding disorders vascular disease platelet function tests endothelial activation markers hemorrhage 785 788 4 02/17/21 20210215 NES 210215 I Osteogenesis imperfecta i (OI) is a genetic disorder of connective tissue affecting bone formation and strength, resulting in susceptibility to spontaneous fracture. Based on Elbatarny's study, OI patients were classified according to their BS.3 BS < 3 correspond to patients with no evidence of bleeding history (OI NB for OI non-bleeders) and a BS >= 3 corresponds to patients with features of bleeding (OI B for OI bleeders). PHOTO (COLOR): 1 Determination of circulating VWF antigen level (A), VWF activity (B), secreted Thrombomodulin (C) and secreted E-selectin in OI group (D), OI NB and OI B subgroups. Platelet aggregation responses to several agonists expressed as maximal amplitude (% aggregation) (MA) after 4 min in the OI group, and in the OI NB and OI B subgroups. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF